MCL1 and hematologic disorder: Although venetoclax has proven efficacious for hematological malignancies, relapse is common and multiple resistance mechanisms have been described, including mutations in BCL-2, upregulation of MCL-1 and BCL-XL, TP53 dysfunction, and BAX loss [123,124,125,126].